One in three people lives with a form of neurodegenerative disease worldwide, amounting to over three billion people. While the rate of disease is so high, treatment options are still limited. Scientists and researchers have been working to understand what exactly causes this type of cognitive decline so they can develop new treatments, but it has proven to be a challenge—one which Neuropeutics is tackling.
Neuropeutics is developing novel therapies targeting a specific protein linked to several neurodegenerative diseases (TDP-43). The accumulation of this protein has been linked to the progression of cognitive and motor decline, which is what makes this type of treatment especially promising.
The company has created multiple disease models to recapitulate and measure harmful changes in protein levels associated with neurodegenerative diseases (like TDP-43). This tool could help researchers better understand disease progression and evaluate the effectiveness of future treatments.
